A C. Elegans-To-Mouse Discovery Framework For Prioritizing Sarcopenia Interventions
Sarcopenia, the age-related decline in muscle mass and function, currently lacks an approved treatment, largely due to the challenges of efficiently identifying promising interventions. Traditional methods, relying heavily on aged-mouse models, are time-consuming and costly, making it difficult to evaluate the vast number of potential therapies, which range from conventional drugs to natural products and dietary compounds.
To overcome this hurdle, researchers have developed an innovative discovery framework that leverages the tiny worm C. elegans as an initial screening tool. This approach allows for the rapid assessment of how different compounds affect movement, muscle health, and overall aging processes in a living organism. The worm’s short lifespan and genetic similarities to humans in key aging pathways make it an ideal model for quickly sifting through many candidates.
Interventions that show promise in C. elegans are then prioritized for further, more detailed investigation in mouse models. The framework focuses on preserving age-related function as a primary selection criterion, supported by evidence of conserved biological mechanisms like mitochondrial health, cellular waste removal (proteostasis), and gut-muscle communication. This streamlined process, exemplified by compounds such as urolithin A, norharmane, and spermidine, aims to significantly accelerate the discovery of effective treatments for sarcopenia, ultimately improving muscle health and quality of life in aging populations.
Source: link to paper